Immune Pharmaceuticals Ltd., a privately held Israeli company, and American EpiCept Corporation, announced that they have entered into a definitive merger agreement. The transaction is anticipated to close during the first quarter of 2013. The combined company, to be named Immune Pharmaceuticals, Inc., will be primarily focused on developing antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer.
Related posts
Red Algae Can Treat Wounds And Infections
January 26, 2023
Freight Planner Lists on Nasdaq And Raises $80M
January 26, 2023
$6M Investment For “Lettuce Milk” Startup
January 25, 2023
Israel Has World’s Best Value Internet
January 25, 2023
Facebook comments